Shares of AXT Inc. surged 8.2% to $118.49 in pre-market trading Tuesday, extending a two-day rebound from a punishing selloff that lopped nearly 22% off the stock between May 27 and May 29. The recovery raises a pointed question: whether the company's fundamentals justify a valuation that has ballooned on AI enthusiasm. AXT's AI-Fueled Rally Resumes After a Brutal Selloff — But Can a $27 Million Revenue Company Justify a Sky-High Valuation?
Shares of AXT Inc. jumped 8.2% to $118.49 in pre-market trading Tuesday, adding to a two-session bounce that has recouped roughly half of a 22% slide from last week's peak of $132.60. Investors are buying the dip in a stock that has become one of Wall Street's most volatile bets on AI infrastructure — but the gap between the hype and the hard numbers remains enormous.
Strong Earnings Sparked the Rally, but the Stock Ran Far Ahead of Them
AXT posted Q1 revenue of $26.9 million, up 38.7% year-over-year, and reported an adjusted loss of just $0.01 per share — far better than the -$0.05 analysts expected.
Indium phosphide — a specialized wafer used in the high-speed optical links that connect AI data centers — contributed $13.6 million, over half of total sales. Those are real improvements. But the stock has gained roughly 7,000% over the past year , which means even a solid beat can't keep up with pricing that already assumes massive future growth.
A $100 Million-Plus Backlog Gives Visibility — Export Permits Could Erase It
Management flagged an order backlog above $100 million tied directly to AI and data-center upgrades.
For Q2, AXT is guiding earnings per share of $0.06–$0.08, versus the Street's expectation for a $0.01 loss — a dramatic swing toward profitability. The catch: the company faces challenges obtaining export permits, which could impact future revenue and growth. For a firm whose manufacturing runs through China-based subsidiary Beijing Tongmei, geopolitical risk isn't theoretical — it's operational.
A Massive Capital Raise Funds Growth but Dilutes Shareholders
AXT announced a $632.5 million capital raise to expand indium phosphide capacity , pricing 8.56 million shares at $64.25 — initially hitting the stock on dilution fears.
The CEO said the company plans to double its indium phosphide output to $35 million per quarter by year-end , with longer-term targets reaching $65–70 million. Execution here is everything: the raised capital only pays off if orders convert to shipments at improved margins.
Valuation Has Decoupled from Fundamentals
The market is valuing AXT's trailing revenue of roughly $88 million at about 60 times sales and nearly 20 times book value.
With negative trailing margins and sky-high valuation ratios, the bull case rests squarely on execution of the capacity buildout and continued AI demand. Any quarterly miss or permit delay could trigger another violent selloff like last week's. AXT is no longer a sleepy materials company — it's a leveraged bet on whether AI spending will sustain the most speculative corner of the semiconductor supply chain.